abstract |
Novel anti-viral agents of Formula (I) wherein:A represents OR?1, NR1R2, or R1¿ wherein R?1 and R2¿ are hydrogen, C¿1-6?alkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; or R?1 and R2¿ together with the nitrogen atom to which they are attached form a 5 or 6 membered saturated cyclic group; B represents C(O)R3 wherein R3 is C¿1-6?alkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; C represents C1-6alkyl, aryl, heteroaryl or heterocyclyl; D represents a saturated or unsaturated optionally substituted 5-membered heterocyclic ring; E represents hydrogen or C1-6alkyl; F represents hydrogen, C1-6alkyl, aryl or heteroaryl; and G represents hydrogen, C1-6alkyl, heterocyclylalkyl, arylalkyl or heteroarylalkyl; and salts and solvates thereof, processes for their preparation and methods of using them in HCV treatment are provided. |